Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,287 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06220032 | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma(HO170DLBCL) | recruiting | Phase 3 | 324 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06452277 | A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)(SOHO-02) | recruiting | Phase 3 | 555 |
| BayerINDUSTRY |
| 36 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT06561386 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%(RELATIVITY1093) | recruiting | Phase 3 | 1,000 | Bristol-Myers SquibbINDUSTRY | 31 | Sep 23, 2026 | clinicaltrials |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 416 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT06619587 | A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 410 | Genentech, Inc.INDUSTRY | 11 | Sep 23, 2026 | clinicaltrials |
| NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 25 | Sep 23, 2026 | clinicaltrials |
| NCT06888063 | Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside the Liver Treatable by Surgery(PUMP IV) | recruiting | Phase 2 | 40 | Erasmus Medical CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07063745 | A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion(MountainTAP-29) | recruiting | Phase 2 / Phase 3 | 590 | Bristol-Myers SquibbINDUSTRY | 34 | Sep 23, 2026 | clinicaltrials |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-02) | recruiting | Phase 3 | 1,000 | Olema Pharmaceuticals, Inc.INDUSTRY | 23 | Sep 23, 2026 | clinicaltrials |
| NCT07221357 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 990 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 23, 2026 | clinicaltrials |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 23, 2026 | clinicaltrials |
| NCT03839771 | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy(HOVON150AML) | active not recruiting | Phase 3 | 968 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 15 | Sep 22, 2026 | clinicaltrials |
| NCT05939414 | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.(PSMA-DC) | recruiting | Phase 3 | 450 | Novartis PharmaceuticalsINDUSTRY | 27 | Sep 22, 2026 | clinicaltrials |
| NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | recruiting | Phase 1 / Phase 2 | 534 | Revolution Medicines, Inc.INDUSTRY | 7 | Sep 22, 2026 | clinicaltrials |
| NCT06140836 | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | active not recruiting | Phase 3 | 190 | Bristol-Myers SquibbINDUSTRY | 21 | Sep 22, 2026 | clinicaltrials |
| NCT06151574 | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | active not recruiting | Phase 3 | 428 | Boehringer IngelheimINDUSTRY | 26 | Sep 22, 2026 | clinicaltrials |
| NCT06440967 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy | active not recruiting | Phase 3 | 982 | Astellas Pharma Global Development, Inc.INDUSTRY | 11 | Sep 22, 2026 | clinicaltrials |
| NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | recruiting | Phase 3 | 630 | Mirati Therapeutics Inc.INDUSTRY | 35 | Sep 22, 2026 | clinicaltrials |
| NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | recruiting | Phase 2 / Phase 3 | 500 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 22, 2026 | clinicaltrials |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 750 | AmgenINDUSTRY | 18 | Sep 22, 2026 | clinicaltrials |
| NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors(FiREBOLT) | recruiting | Phase 1 | 241 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer(FRAmework-01) | recruiting | Phase 3 | 1,630 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 22, 2026 | clinicaltrials |
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract(FORAGER-2) | recruiting | Phase 3 | 450 | Eli Lilly and CompanyINDUSTRY | 19 | Sep 22, 2026 | clinicaltrials |
| NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | recruiting | Phase 2 | 170 | Mirati Therapeutics Inc.INDUSTRY | 20 | Sep 22, 2026 | clinicaltrials |
| NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma(DAWN-303) | recruiting | Phase 3 | 588 | Incyte CorporationINDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT04295811 | Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC(ESOGUARDBE2) | active not recruiting | N/A | 784 | Lucid Diagnostics, Inc.INDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT04503577 | Prospective Bladder Cancer Infrastructure (ProBCI)(ProBCI) | recruiting | — | 3,600 | Prospective Bladder Cancer Infrastructure FoundationOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04523428 | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | recruiting | Phase 2 | 60 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 3 | Sep 21, 2026 | clinicaltrials |
| NCT05041309 | Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies | enrolling by invitation | — | 1,500 | Kite, A Gilead CompanyINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT05117242 | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | terminated | Phase 2 | 125 | GenmabINDUSTRY | 9 | Sep 21, 2026 | clinicaltrials |
| NCT05259709 | A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab | recruiting | Phase 1 | 50 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06834074 | Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors(NVL-655-EAP) | available | — | — | Nuvalent Inc.INDUSTRY | 12 | Sep 21, 2026 | clinicaltrials |
| NCT03435796 | Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | recruiting | Phase 2 / Phase 3 | 1,541 | CelgeneINDUSTRY | 22 | Sep 18, 2026 | clinicaltrials |
| NCT05948943 | Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.(EPIK-L1) | recruiting | Phase 2 / Phase 3 | 232 | Novartis PharmaceuticalsINDUSTRY | 12 | Sep 18, 2026 | clinicaltrials |
| NCT06050122 | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome | completed | Phase 3 | 113 | Sol-Gel Technologies, Ltd.INDUSTRY | 7 | Sep 18, 2026 | clinicaltrials |
| NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 26 | Sep 18, 2026 | clinicaltrials |
| NCT06952803 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation(EvoPAR-PR02) | recruiting | Phase 3 | 700 | AstraZenecaINDUSTRY | 28 | Sep 18, 2026 | clinicaltrials |
| NCT06991556 | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | active not recruiting | Phase 2 | 168 | Novartis PharmaceuticalsINDUSTRY | 15 | Sep 18, 2026 | clinicaltrials |
| NCT07047118 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | active not recruiting | Phase 2 | 138 | Novartis PharmaceuticalsINDUSTRY | 15 | Sep 18, 2026 | clinicaltrials |
| NCT03486873 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | recruiting | Phase 3 | 3,500 | Merck Sharp & Dohme LLCINDUSTRY | 51 | Sep 17, 2026 | clinicaltrials |
| NCT04425967 | Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas(SCOPES) | active not recruiting | N/A | 168 | The Netherlands Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05705921 | Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer | active not recruiting | N/A | 484 | The Netherlands Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05827016 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,230 | Bristol-Myers SquibbINDUSTRY | 34 | Sep 17, 2026 | clinicaltrials |
| NCT06284304 | A Pilot Study of Dose dE-eScalaTion IN prostATe radIOtherapy usiNg the MRL(DESTINATION) | completed | N/A | 20 | The Netherlands Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer(Fern-EC-01) | recruiting | Phase 3 | 480 | BioNTech SEINDUSTRY | 26 | Sep 17, 2026 | clinicaltrials |
| NCT06362616 | Preoperative Accelerated Partial Breast Irradiation in Patients With Locally Recurrent or Second Primary Breast Cancer(PAPBI-3) | recruiting | N/A | 31 | The Netherlands Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT06863272 | A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | recruiting | Phase 1 / Phase 2 | 360 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 17, 2026 | clinicaltrials |
Data updated 5 days agoSource updated unknownsource: clinicaltrials